• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

In view of the increasing complexity of both cardiovascular implantable electronic devices
(CIEDs) and patients in the current era, practice guidelines, by necessity, have become …

Background: Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death
(SCD) in children and young adults. Our objective was to develop and validate a SCD risk …

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often
inherited primary cardiac disease, has now transformed into a contemporary highly treatable …

Aims Childhood-onset hypertrophic cardiomyopathy (HCM) is far less common than adult-
onset disease, thus natural history is not well characterized. We aim to describe the …

Sudden cardiac death and ventricular arrhythmias are a global health issue. Recently, a
new guideline for the management of ventricular arrhythmias and prevention of sudden …

The classes of recommendations and levels of evidence in these guidelines were
determined and described according to the “Guidelines for the treatment of acute and …